Mild Cognitive Impairment, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia
Conditions
Keywords
Alzheimer Disease (AD), Mild cognitive impairment (MCI), Brain Diseases, Nervous System Disorders, Neurodegenerative Diseases, Dementia, Cognitive impairment
Brief summary
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1. What findings can be used to earlier detect patients that will develop Alzheimers? 2. Which differences are seen between healthy and cognitively impaired patients? 3. Which differences are seen between patients with Alzheimers disease? Participants will undergo: * Cognitive tests * Magnetic resonance imaging (MRI) * Electroencephalography (EEG) * Blood sample collection * Fecal sample collection * A randomized group will undergo polysomnography analysis.
Detailed description
The projects aims to map brain changes in patients with mild cognitive impairment (MCI) and Alzheimer's Disease (AD) by combining different assesment modalities. In the MRI, researchers will get the opportunity to analyse both structural and functional brain changes. In the EEG, changes in elctrical activites will be measured. The blood samples allow researchers to analyse specific dementia and inflammation proteins, while fecal speciments can be used to assess bacterial composition. Additionally, the cognitive testing allow to assess the specific part of cognitive function which is affected.
Interventions
BIOLOGICALFecal samples
Analysis of bacterial composition.
DEVICEMRI Scanning
MRI scanning with volumetric, resting and activity-based sequences.
DEVICE64-channel EEG
EEG to quantifiy electric activity.
DEVICEPolysomnography
A randomized group will undergo polysomnography.
BIOLOGICALBlood samples
Analysis of specific blood biomarkers.
BEHAVIORALCognitive tests
Interview-based cognitive tests for assesment of cognitive levels.
Sponsors
Norwegian University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* MCI and AD according to relevant ICD-criterias. * Control cohort is age and gender matched with other cohorts.
Exclusion criteria
* Uneligibility for any of the planned neuroimagery devices (MRI, EEG) * AD diagnosis before the age of 65 (Early-onset AD). * Brain tumor * Traumtic head injury * Earlier neurosurgery * Other neyrodegenerative diseases (i.e Parkinson and ALS) * Diseases related to inflammation and auto-immunity (i.e MS)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MCI-AD converters | 5 years | Identify biomarker profiles unique for patients with MCI that develop AD for earlier prediction. |
| AD-subclassification | 5 years | Identify biomarker profiles that can assist in a more thorough AD-classification |
Countries
Norway
Contacts
Primary ContactAxel Sandvig, Prof., MD, PhD
Outcome results
None listed